RadNet Stock Is Estimated To Be Significantly Overvalued
- By GF Value
The stock of RadNet (NAS:RDNT, 30-year Financials) gives every indication of being significantly overvalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $22.34 per share and the market cap of $1.2 billion, RadNet stock shows every sign of being significantly overvalued. GF Value for RadNet is shown in the chart below.
Because RadNet is significantly overvalued, the long-term return of its stock is likely to be much lower than its future business growth, which averaged 2.7% over the past five years.
Link: These companies may deliever higher future returns at reduced risk.
Since investing in companies with low financial strength could result in permanent capital loss, investors must carefully review a company's financial strength before deciding whether to buy shares. Looking at the cash-to-debt ratio and interest coverage can give a good initial perspective on the company's financial strength. RadNet has a cash-to-debt ratio of 0.09, which ranks in the bottom 10% of the companies in the industry of Medical Diagnostics & Research. Based on this, GuruFocus ranks RadNet's financial strength as 3 out of 10, suggesting poor balance sheet. This is the debt and cash of RadNet over the past years:
It is less risky to invest in profitable companies, especially those with consistent profitability over long term. A company with high profit margins is usually a safer investment than those with low profit margins. RadNet has been profitable 9 over the past 10 years. Over the past twelve months, the company had a revenue of $1.1 billion and loss of $0.31 a share. Its operating margin is 4.24%, which ranks in the middle range of the companies in the industry of Medical Diagnostics & Research. Overall, the profitability of RadNet is ranked 6 out of 10, which indicates fair profitability. This is the revenue and net income of RadNet over the past years: